Overview
Mometasone furoate is a synthetic glucocorticoid steroid developed for its potent anti-inflammatory effects. First approved by the FDA in 1987, it has become a cornerstone in managing dermatological and respiratory conditions due to its localized action and minimal systemic side effects. Its molecular structure includes a furoate ester group, enhancing lipid solubility for better skin penetration. As a Class III mid-potency steroid, it strikes a balance between efficacy and safety, making it suitable for medium-term use. Pharmaceutical formulations include creams, ointments, nasal sprays, and dry powder inhalers, with concentrations typically ranging from 0.1% to 0.5%.
Physical and Chemical Properties
Mometasone furoate crystallizes as a white to off-white powder with a melting point around 218-220°C, where it begins to decompose. The compound exhibits limited water solubility (0.03 mg/mL at 25°C) but dissolves readily in organic solvents like methanol, aiding formulation into topical and inhaled products. Its stability profile requires protection from light and humidity. The presence of chlorine atoms and a conjugated diene system in its structure contributes to its receptor binding affinity, while the furoate ester prolongs tissue retention. Spectroscopic characterization typically shows UV absorption maxima at 238 nm.
Main Applications
In dermatology, mometasone furoate is primarily used to treat inflammatory skin disorders such as atopic dermatitis, psoriasis, and seborrheic dermatitis. Clinical studies demonstrate its ability to reduce erythema, scaling, and pruritus with twice-daily application, often showing results within 3-5 days. For respiratory conditions, it serves as a maintenance therapy for allergic rhinitis (nasal spray) and asthma (inhalation powder). Its localized action minimizes adrenal suppression risks compared to systemic steroids. Off-label uses include oral lichen planus and vulvar lichen sclerosus, though these require medical supervision.
Safety and Storage
Proper storage involves airtight containers at controlled room temperature (20-25°C) with desiccants to prevent hydrolysis. Degradation products include 9α,11β-epoxide and 17-keto derivatives, which should be monitored in stability testing. Safety protocols mandate PPE during handling to avoid inhalation or skin contact. Chronic use beyond 4 weeks requires medical monitoring for hypothalamic-pituitary-adrenal (HPA) axis suppression. Pediatric applications are generally limited to children over 2 years old, with adjusted dosing based on body surface area.
B2B Procurement Guide
Bulk pharmaceutical buyers should prioritize suppliers with active DMF (Drug Master File) submissions to regulatory agencies. Key quality parameters include HPLC purity ≥98.5%, residual solvent levels per ICH guidelines, and particle size distribution (critical for inhalation products). Contracts should specify batch-to-batch consistency testing and stability data supporting at least 24-month shelf life. For topical formulations, micronized grades (D90 <10μm) ensure uniform dispersion. Current market trends show increasing demand for GMP-certified manufacturers in India and China, though EU/US facilities command premium pricing.